# A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive

> **NCT05007080** · PHASE2 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 304 (actual)

## Conditions studied

- Coronavirus Disease-2019 (COVID-19) Prevention

## Interventions

- **BIOLOGICAL:** Ad26.COV2.S

## Key facts

- **NCT ID:** NCT05007080
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-27
- **Primary completion:** 2023-08-14
- **Final completion:** 2023-08-14
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007080, "A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05007080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*